MediWound (MDWD) Set to Announce Quarterly Earnings on Wednesday

MediWound (NASDAQ:MDWD) is scheduled to release its earnings data before the market opens on Wednesday, August 14th. Analysts expect MediWound to post earnings of ($0.42) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

MediWound (NASDAQ:MDWD) last issued its earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. The company had revenue of $4.96 million during the quarter, compared to the consensus estimate of $4.65 million. On average, analysts expect MediWound to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Price Performance

Shares of NASDAQ MDWD opened at $17.95 on Tuesday. MediWound has a 1-year low of $7.10 and a 1-year high of $24.00. The business’s fifty day moving average price is $17.32 and its two-hundred day moving average price is $16.14. The firm has a market capitalization of $166.65 million, a PE ratio of -12.91 and a beta of 0.81.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MDWD shares. Maxim Group lifted their price target on MediWound from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price target on shares of MediWound in a report on Tuesday, July 16th. Finally, StockNews.com upgraded shares of MediWound to a “sell” rating in a report on Monday, August 5th.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.